[go: up one dir, main page]

LU91271I2 - Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) - Google Patents

Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)

Info

Publication number
LU91271I2
LU91271I2 LU91271C LU91271C LU91271I2 LU 91271 I2 LU91271 I2 LU 91271I2 LU 91271 C LU91271 C LU 91271C LU 91271 C LU91271 C LU 91271C LU 91271 I2 LU91271 I2 LU 91271I2
Authority
LU
Luxembourg
Prior art keywords
tysabri
natalizumab
pharmaceutically acceptable
acceptable derivatives
treatment
Prior art date
Application number
LU91271C
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of LU91271I2 publication Critical patent/LU91271I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91271C 1994-01-25 2006-08-02 Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) LU91271I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (fr) 1994-01-25 1995-01-25 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Publications (1)

Publication Number Publication Date
LU91271I2 true LU91271I2 (fr) 2006-10-02

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91271C LU91271I2 (fr) 1994-01-25 2006-08-02 Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)

Country Status (21)

Country Link
EP (2) EP0804237B8 (fr)
JP (5) JP4115517B2 (fr)
KR (1) KR100367948B1 (fr)
CN (1) CN1211123C (fr)
AT (1) ATE333895T1 (fr)
AU (1) AU703152B2 (fr)
CA (1) CA2182013C (fr)
DE (2) DE69535133T2 (fr)
DK (2) DK1759709T3 (fr)
ES (2) ES2424292T3 (fr)
FI (1) FI117509B (fr)
FR (1) FR06C0024I2 (fr)
HU (1) HU220799B1 (fr)
LU (1) LU91271I2 (fr)
MX (1) MX9602971A (fr)
NL (1) NL300238I2 (fr)
NO (3) NO319867B1 (fr)
NZ (1) NZ279730A (fr)
PL (1) PL181827B1 (fr)
PT (1) PT804237E (fr)
WO (1) WO1995019790A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (fr) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Methode permettant de chasser les leucocytes infiltres dans un tissu
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DK1113810T3 (da) * 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
SK287328B6 (sk) * 1999-04-22 2010-07-07 Biogen Idec Ma Inc. Použitie kompozície obsahujúcej homológ protilátky, ktorý je antagonistom interakcie medzi integrínom nesúcim podjednotku alfa4 a ligandom pre integrín nesúci podjednotku alfa4
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000072881A1 (fr) 1999-06-01 2000-12-07 Biogen, Inc. Anticorps monoclonal bloqueur contre vla-1 et utilisation dudit anticorps pour le traitement de troubles inflammatoires
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2140881B1 (fr) * 1999-12-16 2013-04-17 Biogen Idec MA Inc. Procédés de traitement de maladie hémorragique ou ischémique du système nerveux central, utilisant des antagonistes d'intégrine anti alpha 4
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE200300509A (et) 2001-04-13 2004-08-16 Biogen, Inc. Antikehad VLA-1 vastu
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PT2336184E (pt) * 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
EP1499352A4 (fr) * 2002-04-12 2006-10-11 Medimmune Inc Anticorps anti-interleukine-9 recombinants
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
CA2587597A1 (fr) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Traitement pour la sclerose en plaques
WO2007061679A1 (fr) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. IMMUNOGLOBULINE HUMANISEE REACTIVE AVEC L’INTEGRINE α4β7
DK2034830T3 (da) 2006-05-25 2014-10-27 Biogen Idec Inc Anti-vla-1-antistof til behandling af slagtilfælde
EP2124996A4 (fr) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc Méthodes de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
AR067011A1 (es) * 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
WO2009075388A1 (fr) 2007-12-13 2009-06-18 Tokuyama Corporation Composition photochrome durcissable
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
TWI466681B (zh) 2009-03-20 2015-01-01 Amgen Inc α４β７雜二聚體專一性拮抗抗體
WO2011020874A1 (fr) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 en tant que biomarqueur pour le pronostic et le ciblage pour thérapie dans la dystrophie musculaire de duchenne
MX340683B (es) 2010-04-16 2016-07-21 Biogen Ma Inc Anticuerpos anti-vla-4.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
PH12018502221B1 (en) 2011-05-02 2023-05-10 Millennium Pharm Inc FORMULATION FOR ANTI-a4ß7 ANTIBODY
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN110997714B (zh) * 2017-02-17 2024-05-03 赛诺菲 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
US12043845B2 (en) 2017-06-08 2024-07-23 Polpharma Biologics S.A. Methods of cell culture
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
ATE151642T1 (de) * 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
AU688751B2 (en) * 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
FI962958A0 (fi) 1996-07-24
PT804237E (pt) 2006-10-31
PL181827B1 (pl) 2001-09-28
ATE333895T1 (de) 2006-08-15
NO2017040I1 (no) 2017-08-01
DK0804237T3 (da) 2006-10-16
NO2006008I2 (no) 2009-06-15
MX9602971A (es) 1998-01-31
JP5487382B2 (ja) 2014-05-07
EP1759709A1 (fr) 2007-03-07
CA2182013A1 (fr) 1995-07-27
CN1140413A (zh) 1997-01-15
EP1759709B1 (fr) 2013-02-27
JPH09508272A (ja) 1997-08-26
KR970700513A (ko) 1997-02-12
JP2013165718A (ja) 2013-08-29
FI117509B (fi) 2006-11-15
JP2006045237A (ja) 2006-02-16
JP4115517B2 (ja) 2008-07-09
FI962958L (fi) 1996-09-24
KR100367948B1 (ko) 2003-07-12
NO319867B1 (no) 2005-09-26
NO2006008I1 (no) 2006-08-07
JP2009235078A (ja) 2009-10-15
CA2182013C (fr) 2007-07-17
AU1696095A (en) 1995-08-08
HUT75129A (en) 1997-04-28
DE122006000043I1 (de) 2007-02-15
NO963097D0 (no) 1996-07-24
EP0804237A1 (fr) 1997-11-05
AU703152B2 (en) 1999-03-18
HU9602019D0 (en) 1996-09-30
NO2017040I2 (no) 2018-08-28
DE69535133D1 (de) 2006-09-07
NO963097L (no) 1996-09-24
EP0804237B1 (fr) 2006-07-26
NZ279730A (en) 1998-04-27
PL315634A1 (en) 1996-11-25
ES2270425T3 (es) 2007-04-01
FR06C0024I1 (fr) 2006-10-13
HU220799B1 (hu) 2002-05-28
WO1995019790A1 (fr) 1995-07-27
FR06C0024I2 (fr) 2009-01-02
NL300238I1 (fr) 2006-10-02
ES2424292T3 (es) 2013-09-30
EP0804237B8 (fr) 2006-11-08
DK1759709T3 (da) 2013-06-10
EP0804237A4 (fr) 2003-04-16
JP2013173738A (ja) 2013-09-05
NL300238I2 (nl) 2007-05-01
CN1211123C (zh) 2005-07-20
DE69535133T2 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
LU92912I2 (fr) Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala)
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
MY154009A (en) Anti-alpha v beta 6 antibodies
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
AP9200410A0 (en) Retroviral protease inhibitors.
ATE303362T1 (de) Chalcon-derivate mit antiproliferativer aktivität
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DE69710111D1 (de) Behandlung und Prophylaxe von Pankreatitis
EP0669363A3 (fr) Procédé de préparation de polyorganosilane.
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
ID21920A (id) 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns
DK0517787T3 (da) Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
FR2721314B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
MX9704733A (es) Monomeros de ciclohesan-1-ona 4,4-disubstituidos y compuestos relacionados.
MX9704739A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ona y compuestos relacionados.